Abiopharma

🔍 BOBO DONALD E JR (Executive)

Company: Edwards Lifesciences Corp (EW)

Report Date: 2026-05-11

Detailed Transactions and Holdings:

• Acquired 13,457 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 40,235.25 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 7,469 shares of Common Stock at $79.96 per share (Direct)
  Date: 2026-05-11 | Code: F | equity_swap_involved: 0 | shares_owned_after: 32,766.25 | transaction_form_type: 4
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: H | nature_of_ownership: 401(k) | shares_owned_after: 38,969.58
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-11 | Code: H | nature_of_ownership: By Trust | shares_owned_after: 121,756.00
• Sold 13,457 shares of Performance Rights (Derivative)
  Date: 2026-05-11 | Code: M | Exercise: 2026-05-11 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2

Footnotes:

• F1: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4.
• F2: These Performance Rights expire on May 10, 2030.
• REMARKS: This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.